Mounting Evidence in Neuroprotection- Psilocin demonstrates exciting therapeutic promise.

Posted inALS, Psilocin
Recent scientific studies underscore the potential of psilocin to drive transformative neuroprotective effects by promoting neuroplasticity, reducing inflammation, and modulating microglial function, These findings open avenues for research into ALS and other neurodegenerative diseases, where overlapping mechanisms like oxidative stress and neuronal damage are central to disease progression. At Haim Pharma, we’re leveraging these insights to develop stable, disease-specific psilocin formulations that aim to redefine treatment strategies for neurodegenerative conditions. Note: This post is for informational purposes only and does not constitute medical advice.

Why Psilocin

Posted inPsilocin
Psilocin is a serotonin agonist, modulation of serotonin receptors influences mood, cognition, and motor symptoms associated with the disease. It has been shown to enhance neuroplasticity and promote neurogenesis in preclinical studies, by stimulating Brain-Derived Neurotrophic Factor (BDNF) and its receptor TrkB, psilocin should promote neuronal survival and plasticity. Psilocin's activity at N-Methyl-D-Aspartate (NMDA) receptors could potentially modulate glutamate neurotransmission, influencing excitotoxicity and neuronal death observed in neurodegenerative processes. Psilocin is known to possess anti-inflammatory properties, which should neuroinflammation. Psilocin has been shown to modulate mitochondrial function, this potential should improve mitochondrial health and function in neurons.

The Healing Properties of Psilocin

Posted inPsilocin
Psilocin activates multiple pathways that may counteract neurodegenerative disease effects, potentially reducing symptoms and slowing disease progression. Through preclinical and clinical testing, we aim to assess the safety and efficacy of psilocin for a specific condition, paving the way for future regulatory approval as a pharmaceutical treatment.